Decitabine in Myelodysplastic Syndromes-Reference-Cited by-同舟云学术

Decitabine in Myelodysplastic Syndromes

Published:2005-07 Issue: Volume:42 Page:S23-S31
ISSN:0037-1963
Container-title:Seminars in Hematology
language:en
Short-container-title:Seminars in Hematology

Author:

Saba Hussain I.,Wijermans Pierre W.

Publisher

Elsevier BV

Subject

Hematology

Reference60 articles.

1. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes;Aguayo;Blood,2000

2. Myelodysplastic syndrome is not merely “preleukemia”;Albitar;Blood,2002

3. Effects of 5-aza-2′-deoxycytidine on differentiation and oncogene expression in the human monoblastic leukemia cell line U-937;Attadia;Leukemia,1993

4. Increasing incidence of myelodysplastic syndromes;Aul;Leuk Res,1998

5. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes;Bellamy;Blood,2001

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. regionalpcs: improved discovery of DNA methylation associations with complex traits;2024-05-01

2. Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy;Journal of Translational Medicine;2023-03-31

3. Epigenetic dysregulation in the fragile X-related disorders;Chromatin Signaling and Neurological Disorders;2019

4. DNA Methylation and Carcinogenesis: Current and Future Perspectives;Clinical Epigenetics;2019

5. Safety and clinical activity of 5-aza-2′-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia;British Journal of Haematology;2014-07-26